HuGE Literature Finder
Records
1
-
30
| Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Molecular diagnosis & therapy 2021 Nov . Melosky Barbara, Kambartel Kato, Häntschel Maik, Bennetts Margherita, Nickens Dana J, Brinkmann Julia, Kayser Antonin, Moran Michael, Cappuzzo Federi |
| Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. European review for medical and pharmacological sciences 2021 Oct 25 (20): 6232-6244. Lee H J, Jeong G H, Li H, Kim M S, Kim J S, Park S J, Han Y J, Lee K H, Kronbichler A, Hong S H, Ghayda R A, Luchini C, Nottegar A, Koyanagi A, Smith L, Jacob L, Dragioti E, Radua J, Cargnin S, Terrazzino S, Thompson T, Yon D K, Lee S W, Yang J M, Wasuwanich P, Shin J I, Gamerith |
| Systematic Review and Meta-analysis of the Most Common Genetic Mutations in Esophageal Squamous Cell Carcinoma. Journal of gastrointestinal cancer 2021 Oct . Naseri Amirreza, Salehi-Pourmehr Hanieh, Majidazar Reza, Seraji Parya, Rezazadeh-Gavgani Erfan, Zehtabi Mojtaba, Kiani-Kezbin Hamed, Salehnia Fatemeh, Hassannezhad Sina, Hajikamanj Arash, Raeisi Morta |
| EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis. Cancer immunology, immunotherapy : CII 2021 Sep . Yang Huimin, Zhu Jinxiu, Xiao Rendong, Liu Yuhang, Yu Fanglin, Cai Lin, Qiu Minglian, He F |
| EGFR-plasma mutations in prognosis for non-small cell lung cancer treated with EGFR TKIs: A meta-analysis. Cancer reports (Hoboken, N.J.) 2021 Aug e1544. Phan Thang Thanh, Tran Vinh Thanh, Tran Bich-Thu, Ho Toan Trong, Pho Suong Phuoc, Le Anh Tuan, Le Vu Thuong, Nguyen Hang Thuy, Nguyen Son Truo |
| Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis. Pathology, research and practice 2021 Jul 224 153551. Wu Yongfeng, Ni Heng, Yang Dexin, Niu Yuequn, Chen Kelie, Xu Jinming, Wang Fang, Tang Song, Shi Yu, Zhang Honghe, Hu Jian, Xia Dajing, Wu Yih |
| EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials. Journal of cancer research and therapeutics 2021 Jul 17 (3): 664-670. Zhu Cui-Min, Lian Xiang-Yao, Zhang Hong-Yan, Bai Lu, Yun Wen-Jing, Zhao Ru-Han, Li Qing-Sh |
| Prevalence of Targetable Mutations in Black Patients With Lung Cancer: A Systematic Review and Meta-Analysis. JCO oncology practice 2021 May 17 (5): e629-e636. Costa Philippos A, Saul Eduardo E, Paul Yonette, Iyer Sunil, da Silva Laercio Lopes, Tamariz Leonardo, Lopes Gilber |
| Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis. Medicine 2021 Mar 100 (10): e19713. Zhang Rui, Zhu Jing, Liu Ying, Xin Ying, Wang Ying, Niu Kai, Wei Huafa |
| Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. BioMed research international 2021 8850256. Ma Jie-Tao, Guo Yi-Jia, Song Jun, Sun Li, Zhang Shu-Ling, Huang Le-Tian, Jing Wei, Zhao Jian-Zhu, Han Cheng- |
| Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. Clinical lung cancer 2021 Jan . Chan Sze Wah Samuel, Smith Elliot, Aggarwal Reenika, Balaratnam Karmugi, Chen RuiQi, Hueniken Katrina, Fazelzad Rouhi, Weiss Jessica, Jiang Shirley, Shepherd Frances A, Bradbury Penelope A, Sacher Adrian G, Leighl Natasha B, Xu Wei, Brown M Catherine, Eng Lawson, Liu Geoffr |
| The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis. Annals of palliative medicine 2021 Jan . Cui Saijin, Zhang Yaling, Liu Lu, Li Yan, Zhou Rongmiao, Huang Xi, Cao Shiru, Huo Xiangran, Wang |
| Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients. Frontiers in oncology 2021 11 629394. Chen Rui-Lian, Sun Ling-Ling, Cao Yang, Chen Han-Rui, Zhou Jing-Xu, Gu Chu-Ying, Zhang Ying, Wang Si-Yu, Hou Wei, Lin Li-Z |
| Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer. Frontiers in oncology 2021 11 608608. Shi Xiaoshun, Dong Xiaoying, Zhai Jianxue, Liu Xiguang, Lu Di, Ni Zhen, Wu Hua, Cai Kaic |
| Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis. Experimental oncology 2021 09 43 (3): 252-256. Vlachou M S, Mauri D, Zarkavelis G, Ntellas P, Tagkas C, Gkoura S, Pentheroudakis |
| Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis. BioMed research international 2021 2021 3621828. Lv Fangfang, Sun Liang, Yang Qiuping, Pan Zheng, Zhang Yuh |
| The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis. Thoracic cancer 2021 04 12 (7): 1084-1095. Lin Chutong, Hu Fengling, Chu Hongling, Ren Peng, Ma Shanwu, Wang Jingdi, Bai Jie, Han Xuan, Ma Shaoh |
| Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Current oncology reports 2020 Sep 22 (12): 119. Peravali Monica, Wang Haijun, Kim Chul, Veytsman Iri |
| Impact of programmed death-ligand 1 expression on the patients of stage IV non-small cell lung cancer harboring epidermal growth factor receptor mutation: a systematic review and meta-analysis. Acta oncologica (Stockholm, Sweden) 2020 Aug 1-8. Lee Chia Ching, Soon Yu Yang, Leong Cheng Nang, Koh Wee Yao, Tey Jere |
| The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis. Medicine 2020 Aug 99 (34): e21826. Liu Jing, Li Xuemei, Shao Yinghong, Guo Xiyun, He Jingg |
| First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. Journal of cancer research and clinical oncology 2020 Jul . Landre Thierry, Des Guetz Gaetan, Chouahnia Kader, Duchemann Boris, Assié Jean-Baptiste, Chouaid Christ |
| Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis. Medicine 2020 Jan 99 (3): e18771. Zhou Kenan, Zhao Shishun, Guo Wenlai, Ding L |
| KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. Caspian journal of internal medicine 2020 11 (4): 355-369. Yari Abolfazl, Afzali Asiyeh, Aalipour Mostafa, Nakheai Mehran, Zahedi Mohammad Jav |
| Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis. BioMed research international 2020 2020 2380124. Fan Kui, Zhang Chuan-Long, Qi Yuan-Fu, Dai Xin, Birling Yoann, Tan Zhao-Feng, Cao Fa |
| Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer medicine 2019 Dec . Bylsma Lauren C, Gillezeau Christina, Garawin Tamer A, Kelsh Michael A, Fryzek Jon P, Sangaré Laura, Lowe Kimberly |
| Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis. Medicine 2019 Oct 98 (43): e17705. Huang Lei, Huang Hao, Zhou Xiao-Ping, Liu Jin-Feng, Li Chun-Rong, Fang Min, Wu Jun-Ro |
| EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. Lung cancer (Amsterdam, Netherlands) 2019 Aug 136 6-14. Tang Wenjie, Li Xiaolin, Xie Xueqi, Sun Xindong, Liu Jie, Zhang Jian, Wang Chungang, Yu Jinming, Xie Pe |
| Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Cancers 2019 Aug 11 (9): . Buonerba Carlo, Iaccarino Simona, Dolce Pasquale, Pagliuca Martina, Izzo Michela, Scafuri Luca, Costabile Ferdinando, Riccio Vittorio, Ribera Dario, Mucci Brigitta, Carrano Simone, Picozzi Fernanda, Bosso Davide, Formisano Luigi, Bianco Roberto, De Placido Sabino, Di Lorenzo Giusep |
| Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ (Clinical research ed.) 2019 10 367 l5460. Zhao Yi, Liu Jingting, Cai Xiuyu, Pan Zhenkui, Liu Jun, Yin Weiqiang, Chen Hanzhang, Xie Zhanhong, Liang Hengrui, Wang Wei, Guo Zhihua, Zhao Shen, Liang Wenhua, He Jianxi |
| Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis. Therapeutic advances in medical oncology 2019 11 1758835919891652. Zhang Zhonghan, Zeng Kangmei, Zhao Shen, Zhao Yuanyuan, Hou Xue, Luo Fan, Lu Feiteng, Zhang Yaxiong, Zhou Ting, Ma Yuxiang, Yang Yunpeng, Fang Wenfeng, Huang Yan, Zhang Li, Zhao Hongy |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jan 12, 2022
- Content source: